These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34297159)

  • 1. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
    Mateu-Albero T; Juárez-Sánchez R; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C; Cuesta-Mateos C
    Cancer Immunol Immunother; 2022 Mar; 71(3):627-636. PubMed ID: 34297159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.
    Mateu-Albero T; Marcos-Jimenez A; Delgado-Wicke P; Terrón F; Loscertales J; López-Matencio JMS; Muñoz-Calleja C; Cuesta-Mateos C
    Hematol Oncol; 2023 Dec; 41(5):869-876. PubMed ID: 37545392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.
    Cuesta-Mateos C; Juárez-Sánchez R; Mateu-Albero T; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C
    MAbs; 2021; 13(1):1917484. PubMed ID: 33944659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
    Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
    Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
    Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
    Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients.
    Mateu-Albero T; Marcos-Jimenez A; Wissmann S; Loscertales J; Terrón F; Stein JV; Muñoz-Calleja C; Cuesta-Mateos C
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
    Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
    Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia.
    Rey-Barroso J; Munaretto A; Rouquié N; Mougel A; Chassan M; Gadat S; Dewingle O; Poincloux R; Cadot S; Ysebaert L; Quillet-Mary A; Dupré L
    Haematologica; 2024 Mar; 109(3):809-823. PubMed ID: 37381758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.
    Cuesta-Mateos C; Brown JR; Terrón F; Muñoz-Calleja C
    Front Immunol; 2021; 12():662866. PubMed ID: 33841445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
    Chen TL; Harrington B; Truxall J; Wasmuth R; Prouty A; Sloan S; Lehman AM; Sampath D; Orlemans E; Baiocchi RA; Alinari L; Byrd JC; Woyach JA; Hertlein E
    J Hematol Oncol; 2021 Feb; 14(1):36. PubMed ID: 33627156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
    Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
    Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
    Timofeeva N; Gandhi V
    Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
    Seda V; Vojackova E; Ondrisova L; Kostalova L; Sharma S; Loja T; Mladonicka Pavlasova G; Zicha D; Kudlickova Peskova M; Krivanek J; Liskova K; Kren L; Benes V; Musilova Litzmanova K; Borsky M; Oppelt J; Verner J; Pospisilova S; Brychtova Y; Panovska A; Tan Z; Zhang S; Doubek M; Amruz Cerna K; Mayer J; Mraz M
    Blood; 2021 Sep; 138(9):758-772. PubMed ID: 33786575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.